Vmbook Online ordering

Ophthalix Inc

Ophthalix Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for eye diseases. The company's lead product candidate is ONL1204, a novel, potential first-in-class small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) for the treatment of diabetic macular edema (DME) and other retinal diseases.

As of my knowledge up to 2021, Ophthalix Inc is not a publicly traded company and hence not listed on any stock exchange including the USA stock exchanges such as NASDAQ or NYSE. Therefore, it is not possible to buy or sell shares of the company on the public market. However, the company's status can change, and it may choose to go public in the future through an Initial Public Offering (IPO). It is recommended to check the latest and official sources for the most up-to-date information.